Ventana Sublicensing IP from Gen-Probe for ERG Protein Measurement | GenomeWeb

NEW YORK (GenomeWeb News) – Ventana Medical Systems today announced it is co-exclusively sublicensing certain patents and patents applications from Gen-Probe for the worldwide in vitro diagnostic rights to measure ERG protein expression by immunohistochemistry in prostate tissue.

Ventana, a Roche company, said that the license complements its existing worldwide co-exclusive sublicense under certain patents and patent applications for in situ hybridization for measuring ETS gene rearrangements, such as ERG gene rearrangements in tissue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.